Since the initial estimates of 27% and 77% of CDKN2A/B deletions in the early T-cell precursor ALL (ETP-ALL) and non-ETP patients (p = 0.0036) [84], respectively, several studies have produced results concordant with this association. Here, CDKN2A is linked to acute lymphoblastic leukemia.